Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral - SARS-CoV-2 and cancer 1

LBA80 - Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)


18 Sep 2020


Mini Oral - SARS-CoV-2 and cancer 1


COVID-19 and Cancer

Tumour Site


Markus Joerger


Annals of Oncology (2020) 31 (suppl_4): S1142-S1215. 10.1016/annonc/annonc325


M. Joerger1, Y. Metaxas2, A. Schmitt3, D. Koeberle4, K. Zaman5, D. Betticher6, N. Mach7, C. Renner8, M.T. Mark9, U. Petrausch10, C.B. Caspar11, C. Britschgi12, C. Taverna13, F. Zenger14, W. Mingrone15, J. Schulz16, C. Kopp17, S. Hayoz18, A. Stathis19, R. von Moos20

Author affiliations

  • 1 Medical Oncology And Hematology Department, Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 2 Oncology/hematology, Kantonsspital Graubünden, 7000 - Chur/CH
  • 3 Medical Oncology, University Hospital Basel, 4031 - Basel/CH
  • 4 Medical Oncology, Claraspital, 4058 - Basel/CH
  • 5 Oncology Dept., CHUV - Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH
  • 6 Service D'oncologie, Clinique De Médecine, Hôpital Fribourgois HFR, 1708 - Fribourg/CH
  • 7 Medical Oncology, Hôpitaux Universitaires de Genève - HUG, 1211 - Geneva/CH
  • 8 Medical Oncology, Klinik Hirslanden, 8032 - Zurich/CH
  • 9 Oncology/hematology Department, Kantonsspital Graubünden, 7000 - Chur/CH
  • 10 Medical Oncology, OnkoZentrum Zürich, 8038 - Zürich/CH
  • 11 Medical Oncology, Kantonsspital Baden, 5404 - Baden/CH
  • 12 Department Of Medical Oncology And Hematology, University Hospital Zürich, 8091 - Zurich/CH
  • 13 Medical Oncology, Kantonsspital, 8596 - Münsterlingen/CH
  • 14 Medical Oncology, University Hospital, 3010 - Bern/CH
  • 15 Medical Oncology, Kantonsspital Solothurn, 4500 - Solothurn/CH
  • 16 Swiss Clinical Cancer Research Group, Swiss Clinical Cancer Research Group, 3008 - Bern/CH
  • 17 Coordinating Center, Swiss Group for Clinical Cancer Research, 3008 - Bern/CH
  • 18 Sakk - Swiss Group For Clinical Cancer Research, SAKK - Swiss Group for Clinical Cancer Research, 3008 - Bern/CH
  • 19 Medical Oncology Department, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), 6500 - Bellinzona/CH
  • 20 Medical Oncology, Kantonsspital Graubünden, 7000 - Chur/CH


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract LBA80


There is ongoing controversy regarding the outcome of COVID-19 in cancer patients. This is one of few registries on the impact of COVID-19 in cancer patients in a country severly affected by the pandemic.


This cohort study is collecting data on symptomatic Sars-CoV-2 infected patients with a cancer diagnosis from 23 Swiss sites, starting March 1, 2020. The main objective of the study is to assess the outcome of COVID-19 infection in patients with solid and hematological malignancies, while the main secondary objective is to define prognostic factors of COVID-19 outcome.


With a cutoff date of July 16, 2020, 357 patients with a diagnosis of cancer and symptomatic COVID-19 were included into this first analysis. The most frequent malignancies were breast in 63 cases (18%), lung in 40 cases (11%), prostate cancer in 24 cases (7%) and myeloma in 16 cases (5%), with 104 (38%) patients having non-curative disease. Anticancer treatment within 3 months prior to the diagnosis of COVID-19 included chemotherapy in 65 patients (18%), targeted therapy in 54 patients (15%), steroids in 39 (11%), checkpoint inhibitors in 22 (6%) or no anticancer treatment in 155 patients (43%). 230 patients (65%) were hospitalized for COVID-19 or were already in hospital; 167 of the hospitalized patients (73%) required oxygen treatment, 43 patients (19%) intensive care, 31 (14%) invasive ventilation. 63 patients died from COVID-19 infection, resulting in a mortality rate of 18%. Significant risk factors for death included age ≥65 versus <65 (HR 5.84, p<0.001) and non-curative versus curative disease (HR 2.34, p=.01). Neither male versus female gender (HR 1.59, p=0.12), type of cancer, geographic region, chemotherapy (HR 1.31, p=0.44), cardiovascular disease (HR 2.25, p=0.09) nor pulmonary comorbidity (HR 0.93, p=0.86) were significant risk factors for death.


We found a COVID-19 mortality rate in real-world cancer patients in a country with a decentralized, high-quality health care system that is substantially higher than in all COVID-19 infected patients in Switzerland (18% versus 5%). The rate of hospitalization and intensive care from COVID-19 in cancer patients is substantial.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Swiss Clinical Cancer Research Group.


Swiss Clinical Cancer Research Group.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.